AMGN Stock Summary and Trading Ideas (Amgen | NASDAQ:AMGN)

Amgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). The 2023 Horizon acquisition brings several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.

Amgen trades on the NASDAQ stock market under the symbol AMGN.

As of February 19, 2025, AMGN stock price climbed to $294.27 with 1,942,780 million shares trading.

AMGN has a beta of 0.72, meaning it tends to be less sensitive to market movements. AMGN has a correlation of 0.11 to the broad based SPY ETF.

AMGN has a market cap of $158.32 billion. This is considered a Large Cap stock.

Last quarter Amgen reported $9 billion in Revenue and $5.31 earnings per share. This beat revenue expectation by $208 million and exceeded earnings estimates by $.23.

In the last 3 years, AMGN traded as high as $346.85 and as low as $211.71.

The top ETF exchange traded funds that AMGN belongs to (by Net Assets): VTI, VOO, QQQ, SCHD, SPY.

AMGN has underperformed the market in the last year with a return of +6.9%, while SPY returned +24.1%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in AMGN shares. However, AMGN has outperformed the market in the last 3 month and 2 week periods, returning +6.4% and +2.6%, while SPY returned +4.5% and +1.9%, respectively. This indicates AMGN has been having a stronger performance recently.

AMGN support price is $288.54 and resistance is $297.06 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AMGN shares will trade within this expected range on the day.